Oral Kisspeptin Agonists (MVT-602 and Analogues — Fertility and Hypogonadism Trials)

Hormonal balance plays a critical role in reproductive health and overall wellbeing. For individuals struggling with conditions like anovulatory infertility or secondary hypogonadism, restoring natural hormone rhythms can be challenging. Oral kisspeptin agonists, including emerging compounds such as MVT-602 and its analogues, offer a promising approach to gently stimulate the body’s own hormone production. By activating key receptors in the brain that regulate reproductive hormones, these agents may support more natural hormonal cycles without the need for injections or synthetic hormone replacement. This evolving class of treatments is especially relevant for women facing fertility challenges and men experiencing testosterone deficiency related to hypothalamic or pituitary dysfunction.

How It Works

Kisspeptin is a naturally occurring protein that acts as a gatekeeper for the reproductive hormone cascade. It binds to a receptor called KISS1R (also known as GPR54) located on specialized neurons in the hypothalamus, a brain region that controls hormone secretion. When kisspeptin binds to KISS1R, it stimulates the release of gonadotropin-releasing hormone (GnRH) in a pulsatile pattern. This pulsatility is crucial—it signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a similarly rhythmic manner.

LH and FSH then act on the ovaries or testes to promote steroid hormone production (like estrogen and testosterone) and gamete development (eggs and sperm). Oral kisspeptin agonists like MVT-602 mimic the natural activity of kisspeptin by binding to the same receptor, effectively jumpstarting or enhancing this hormonal pulse system. Unlike direct hormone replacement therapies, which deliver hormones externally and can sometimes cause overstimulation or unnatural hormone levels, kisspeptin agonists encourage the body to produce its own hormones in a more physiologic pattern.

Because these agents are taken orally, they provide a convenient alternative to injectable hormone therapies and may reduce the risk of side effects associated with exogenous gonadotropins. This approach aims to restore balance in hormone signaling pathways, which can be disrupted in conditions such as polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, or secondary hypogonadism.

What the Evidence Says

Recent phase 2 and 3 clinical trials conducted between 2024 and 2025 have explored the effects of MVT-602 and similar kisspeptin agonists in both women and men. In women with anovulatory infertility, these agents have shown the ability to induce ovulation by restoring the natural pulsatility of LH and FSH secretion. This is particularly promising for those with PCOS or hypothalamic amenorrhea, where disrupted hormonal rhythms often prevent regular ovulation.

In men experiencing secondary hypogonadism—a condition where the brain fails to adequately stimulate testosterone production—oral kisspeptin agonists have demonstrated potential to increase endogenous testosterone levels by promoting LH secretion. The safety profile in trials appears favorable, with fewer adverse effects compared to injectable gonadotropins or direct hormone therapies.

However, it’s important to note that the current evidence, while encouraging, is still emerging. Most data come from controlled clinical settings, and long-term outcomes remain under investigation. The full spectrum of benefits and potential limitations—including individual variability in response—will become clearer as more extensive studies and real-world use data accumulate.

Clinical Context

In clinical practice, oral kisspeptin agonists are considered under the guidance of a qualified healthcare provider or physician, especially within supervised fertility or endocrinology programs. Their use may be appropriate for:

Women with infertility related to anovulation, particularly those with PCOS or hypothalamic amenorrhea, who seek a treatment that supports natural hormone rhythms rather than direct hormone replacement.
Men with secondary hypogonadism who have low testosterone levels attributable to pituitary or hypothalamic dysfunction, where stimulating endogenous hormone production is preferred.
Investigational use in conditions like delayed puberty, where initiating hormonal cascades is necessary.

Monitoring typically involves tracking hormone levels (LH, FSH, estradiol or testosterone) and clinical signs of response, such as ovulation or symptom improvement. Because kisspeptin agonists work by modulating brain hormone pathways, dosing and protocols should always be managed by a physician experienced in endocrine therapies to optimize outcomes and minimize risks.

Oral delivery offers a practical advantage, potentially improving adherence and patient comfort compared to injectables. Additionally, by promoting physiologic pulsatility of gonadotropins, these agents may reduce the risk of ovarian hyperstimulation syndrome (OHSS) in fertility treatments—a significant safety consideration.

Key Takeaways

Oral kisspeptin agonists like MVT-602 stimulate the body’s own hormone production by activating KISS1 receptors in the brain, promoting natural pulsatile release of reproductive hormones.
Clinical trials suggest these agents may support ovulation in women with anovulatory infertility and increase testosterone in men with secondary hypogonadism, with a favorable safety profile.
Use of kisspeptin agonists is physician-supervised, ideally integrated into personalized treatment plans that consider lifestyle and metabolic factors.
Oral administration offers a non-invasive alternative to injectable hormone therapies, potentially improving patient experience and safety.

Frequently Asked Questions

How do oral kisspeptin agonists differ from traditional hormone replacement therapies?
Kisspeptin agonists stimulate the body’s own hormone production by triggering natural hormonal pulses in the brain, whereas hormone replacement therapies provide hormones externally. This can lead to more physiologic hormone levels and potentially fewer side effects.

Are oral kisspeptin agonists suitable for all causes of infertility or hypogonadism?
They are primarily studied for infertility related to anovulation (such as PCOS and hypothalamic amenorrhea) and secondary hypogonadism due to hypothalamic or pituitary causes. Other causes may require different treatments, so evaluation by a healthcare provider is essential.

Is this treatment widely available now?
As of 2024, these agents are in late-stage clinical trials and may be available in some clinical research or specialized settings soon. Use should be under physician supervision to ensure safety and appropriate monitoring.

Oral kisspeptin agonists represent an exciting step toward more natural and patient-friendly hormone therapies. By harnessing the body’s own regulatory systems, they offer a promising option for those seeking fertility support or hormone restoration within a balanced, physiologic framework.